
AAPG Stock Forecast & Price Target
AAPG Analyst Ratings
Bulls say
Ascentage Pharma Group has shown significant commercial growth, with olverembatinib achieving sales of RMB 217.4 million (approximately US$30.3 million) in the first half of 2025, reflecting a remarkable 93% year-over-year increase and cumulative sales surpassing US$100 million since its launch. The company's expanding presence is indicated by its coverage of around 867 hospitals and onboarding of 782 direct-to-patient pharmacies and hospitals, representing a 17% increase compared to the previous year. Furthermore, the favorable market conditions for U.S.-listed Chinese biotechs, marked by improved liquidity and capital formation, contribute positively to the overall outlook for Ascentage Pharma Group.
Bears say
Ascentage Pharma Group's stock outlook is negatively impacted by ongoing downward pressure from volume-based procurement programs, which have begun to affect innovative therapies and may lead to reduced revenue growth and margin erosion due to aggressive NRDL repricing cycles. The company's disappointing clinical trial results, including the failure to meet primary endpoints, raise concerns about its global growth potential and competitive positioning, particularly in the less competitive landscape of myelodysplastic syndrome. Additionally, slow adoption rates in China and the inability of their lead drug, Olverembatinib, to clinically differentiate from established therapies further hinder potential sales and revenue growth.
This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares